Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chugai Releases New Actemra Data, Rides Wave To Submit U.S. FDA Response In Third Quarter

This article was originally published in PharmAsia News

Executive Summary

Chugai Pharmaceutical, the Japanese division of Roche, June 10 released new data on rheumatoid arthritis drug Actemra (tociluzumab), which showed that up to 56 percent of patients with active RA treated with Actemra for more than two years achieved disease remission. Presented at the European League Against Rheumatism annual congress, the remission data provides Roche and Chugai refreshed vigor on its push for still-pending U.S. approval for tociluzumab
Advertisement

Related Content

Despite A Wide Retreat From Discovery Research By Multinationals In Japan, Some Are Staying Put (Part 2 Of 3)
Despite A Wide Retreat From Discovery Research By Multinationals In Japan, Some Are Staying Put (Part 2 Of 3)
Chugai Discloses Actemra Adverse Events In Japan – Will It Impact U.S. Approval?
Roche’s Actemra Delayed By REMS, FDA Study Requirements
Roche’s Actemra Delayed By REMS, FDA Study Requirements
Advertisement
UsernamePublicRestriction

Register

SC071922

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel